Nuchal Translucency Calculator
Use our free Nuchal translucency Calculator to get personalized health results. Based on validated medical formulas and clinical guidelines.
Calculator
Adjust values & calculateValid range: 45-84 mm (11w0d to 13w6d)
Formula
Where NT MoM is the Multiple of the Median, the expected NT median is derived from the crown-rump length using a logarithmic regression model, and the likelihood ratio is computed from the log-Gaussian distribution of NT MoM values in affected versus unaffected pregnancies. The background risk is based on maternal age at delivery.
Last reviewed: January 2026
Worked Examples
Example 1: 30-Year-Old with Normal NT Measurement
Example 2: 38-Year-Old with Elevated NT Measurement
Background & Theory
The Nuchal Translucency Calculator applies the following established principles and formulas. Health and medicine calculators are grounded in validated physiological measurement methods established through decades of clinical research. Body Mass Index, or BMI, is calculated by dividing weight in kilograms by height in meters squared (kg/m²), a formula originating from Adolphe Quetelet's 19th-century statistical work and later codified by the WHO into standard classifications: underweight below 18.5, normal weight 18.5 to 24.9, overweight 25 to 29.9, and obese at 30 and above. Basal Metabolic Rate quantifies the minimum energy required to sustain life at rest. The Mifflin-St Jeor equation, published in 1990 and widely regarded as the most accurate for most adults, calculates BMR as (10 × weight in kg) + (6.25 × height in cm) − (5 × age) ± sex adjustment. The older Harris-Benedict equations, revised in 1984 by Roza and Shizgal, remain in common use. Total Daily Energy Expenditure is derived by multiplying BMR by a physical activity factor ranging from 1.2 for sedentary individuals to 1.9 for extremely active ones, following the methodology validated by doubly labeled water studies. Body fat percentage can be estimated without laboratory equipment using the U.S. Navy circumference method, which uses neck, waist, and hip measurements, or via BMI-derived equations adjusted for age and sex. The Jackson-Pollock skinfold method offers higher precision with calipers. Blood pressure classification, according to the American College of Cardiology and the 2017 ACC/AHA guidelines, defines normal as below 120/80 mmHg, elevated as 120 to 129 systolic, and hypertension stage 1 as 130 to 139 systolic or 80 to 89 diastolic. Target heart rate zones for aerobic exercise are derived from maximum heart rate estimates, most commonly using the formula 220 minus age in years, with moderate-intensity training typically defined as 50 to 70 percent of maximum heart rate and vigorous intensity at 70 to 85 percent, consistent with CDC and American Heart Association guidelines. These thresholds guide safe and effective cardiovascular conditioning.
History
The history behind the Nuchal Translucency Calculator traces back through the following developments. The history of health measurement stretches back to ancient Greece, where Hippocrates around 400 BCE laid the foundation for observational medicine by systematically recording patient symptoms, diet, and environment. His humoral theory, though scientifically superseded, established the principle that the body operates as an interconnected system subject to measurable imbalance. The transformation toward modern medicine accelerated in the 19th century. Louis Pasteur and Robert Koch developed germ theory in the 1860s and 1870s, identifying microorganisms as disease agents and enabling targeted interventions. Florence Nightingale, working during the Crimean War in the 1850s, introduced statistical analysis to nursing practice, demonstrating through data visualization that sanitation reduced mortality. Her work is foundational to evidence-based health measurement. The discovery of vitamins in the early 20th century, beginning with Casimir Funk's coinage of the term in 1912 and culminating in the isolation of vitamins A through K, created the field of nutritional science and gave rise to dietary reference intake frameworks. The World Health Organization, founded in 1948, subsequently established global standards for health metrics, disease classification through the International Classification of Diseases, and recommended daily allowances. The BMI as a clinical screening tool gained traction in the 1970s through Ancel Keys' large-scale epidemiological work, which validated Quetelet's index as a population-level obesity indicator. Through the 1980s and 1990s, the Framingham Heart Study produced landmark data linking cholesterol, blood pressure, and lifestyle factors to cardiovascular disease risk, directly shaping the numeric thresholds still used in health calculators. The evidence-based medicine movement, formalized by Gordon Guyatt and colleagues at McMaster University in the early 1990s, demanded that all health recommendations derive from systematically graded clinical evidence. The digital health era beginning in the 2000s brought these formulas to consumer devices, wearable sensors, and smartphone applications, expanding access to health self-monitoring on a global scale and enabling population-level data collection that continues to refine clinical reference ranges.
Frequently Asked Questions
Formula
NT MoM = Observed NT / Expected NT Median; Risk = Background Age Risk x Likelihood Ratio
Where NT MoM is the Multiple of the Median, the expected NT median is derived from the crown-rump length using a logarithmic regression model, and the likelihood ratio is computed from the log-Gaussian distribution of NT MoM values in affected versus unaffected pregnancies. The background risk is based on maternal age at delivery.
Worked Examples
Example 1: 30-Year-Old with Normal NT Measurement
Problem: A 30-year-old woman has an NT scan at 12 weeks showing CRL of 65 mm and NT measurement of 1.5 mm. Calculate her risk assessment.
Solution: Expected NT median for CRL 65 mm = 10^(-0.3599 + 0.0127 x 65 - 0.0000588 x 65^2) = approximately 1.58 mm\nNT MoM = 1.5 / 1.58 = 0.95 (below median, favorable)\nAge-related background risk for T21 at age 30 = approximately 1 in 626\nLikelihood ratio applied: adjusted risk remains low\nGestational age from CRL: approximately 12.4 weeks
Result: Low Risk - NT is within normal range with MoM of 0.95, indicating reassuring results
Example 2: 38-Year-Old with Elevated NT Measurement
Problem: A 38-year-old woman has CRL of 60 mm and NT measurement of 3.2 mm. Calculate risk and determine follow-up recommendations.
Solution: Expected NT median for CRL 60 mm = approximately 1.48 mm\nNT MoM = 3.2 / 1.48 = 2.16 (significantly elevated)\nAge-related background risk for T21 at age 38 = approximately 1 in 175\nElevated MoM increases likelihood ratio substantially\nCombined adjusted risk is elevated above typical screening cutoff
Result: High Risk - NT of 3.2 mm is above 95th percentile. Further diagnostic testing (NIPT, CVS, or amniocentesis) recommended
Frequently Asked Questions
What is nuchal translucency and why is it measured during pregnancy?
Nuchal translucency (NT) is the measurement of the clear fluid-filled space at the back of a developing baby's neck, visible on ultrasound between 11 and 14 weeks of gestation. This measurement is a critical first-trimester screening marker because increased fluid accumulation in this region is associated with chromosomal abnormalities such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). The NT scan is non-invasive and typically combined with maternal blood tests to calculate a combined risk assessment. A larger NT measurement does not diagnose a condition but indicates the need for further diagnostic testing.
What is a normal nuchal translucency measurement and what values are concerning?
A normal NT measurement is generally below 3.0 mm, with the median value increasing slightly as the fetus grows from about 1.2 mm at 11 weeks to 1.9 mm at 13 weeks and 6 days. Measurements above 3.0 mm are considered elevated and warrant further investigation through diagnostic procedures like chorionic villus sampling or amniocentesis. However, many babies with slightly elevated NT measurements are born perfectly healthy, as the screening has a notable false-positive rate. The measurement must be interpreted in context with crown-rump length, maternal age, and biochemical markers for accurate risk assessment.
What is the crown-rump length and how does it relate to nuchal translucency screening?
Crown-rump length (CRL) is the measurement from the top of the embryo's head to the bottom of its torso, used as the most accurate method for determining gestational age in early pregnancy. For NT screening to be valid, the CRL must be between 45 mm and 84 mm, corresponding to roughly 11 weeks 0 days through 13 weeks 6 days of gestation. The CRL is essential because the expected median NT value changes with gestational age and fetal size, so accurate CRL measurement ensures proper calculation of the MoM value. Incorrect CRL measurements can lead to falsely reassuring or falsely alarming risk calculations.
What happens if the nuchal translucency measurement is elevated or the risk is high?
If the NT measurement is elevated or the calculated risk exceeds the screening cutoff (typically 1 in 250 to 1 in 300), healthcare providers will recommend further diagnostic testing. Options include non-invasive prenatal testing (NIPT) which analyzes cell-free fetal DNA in maternal blood with over 99% accuracy for common trisomies, chorionic villus sampling (CVS) performed at 11-14 weeks, or amniocentesis performed at 15-18 weeks. Both CVS and amniocentesis are definitive diagnostic tests but carry a small risk of miscarriage (approximately 0.5-1%). Genetic counseling is strongly recommended to help parents understand results and make informed decisions.
Can an increased nuchal translucency indicate problems other than chromosomal abnormalities?
Yes, an increased NT measurement can be associated with several conditions beyond chromosomal abnormalities. These include congenital heart defects (which occur in about 5% of fetuses with NT above 3.5 mm but normal chromosomes), skeletal dysplasias, diaphragmatic hernias, and various genetic syndromes such as Noonan syndrome and Smith-Lemli-Opitz syndrome. Significantly elevated NT measurements above 6.0 mm may also indicate fetal hydrops or lymphatic system malformations. When chromosomal testing returns normal results, a detailed fetal echocardiography at 18-22 weeks is recommended to evaluate cardiac structure.
What are the limitations of nuchal translucency screening as a diagnostic tool?
NT screening is a probabilistic assessment, not a definitive diagnosis, which means it has inherent limitations. The detection rate for Down syndrome using NT alone is approximately 70-75%, rising to 85-90% when combined with blood markers. The false-positive rate is approximately 5%, meaning that for every 20 women screened, one may receive a high-risk result despite carrying an unaffected baby. Measurement accuracy depends heavily on sonographer training and technique, gestational age timing, and fetal position during the scan. Additionally, a low-risk NT result does not guarantee the absence of chromosomal abnormalities or other birth defects.
References
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy